HLA-E Antibody (MEM-E/08): sc-51624
- HLA-E Antibody (MEM-E/08) is a mouse monoclonal IgG1, cited in 2 publications, provided at 100 µg/ml
- raised against bacterially expressed recombinant HLA-E refolded with β2-microglubulin and peptide of human origin
- recommended for detection of native surface-expressed HLA-E of human origin by WB, IP and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for HLA-E Antibody (MEM-E/08). This work is in progress.
HLA-E Antibody (MEM-E/08) is a mouse monoclonal IgG1 antibody that detects HLA-E in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and flow cytometry (FCM). HLA-E plays a crucial role in the immune system by presenting a limited set of peptides derived from the leader sequences of other major histocompatibility complex (MHC) class I molecules, which is essential for the regulation of immune responses. This unique function allows HLA-E to interact with inhibitory receptors on natural killer (NK) cells, thereby contributing to the maintenance of immune tolerance and preventing autoimmunity. HLA-E is primarily located on the surface of various cell types, including antigen-presenting cells, where HLA-E serves as a key player in modulating the activity of both T cells and NK cells. By presenting these specific peptides, HLA-E helps to ensure that the immune system can distinguish between self and non-self, which is vital for effective immune surveillance and response. Anti-HLA-E antibody (MEM-E/08) is an invaluable tool for researchers studying immune regulation and the intricate mechanisms of antigen presentation, providing insights into potential therapeutic targets for immune-related diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
HLA-E Antibody (MEM-E/08) References:
- HLA-E expression in diffuse glioma: relationship with clinicopathological features and patient survival. | Wu, Z., et al. 2020. BMC Neurol. 20: 59. PMID: 32066399
- Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E. | Zidi, I. 2020. Hum Immunol. 81: 697-701. PMID: 33046268
- Association of HLA-G, HLA-E and HLA-B*27 with susceptibility and clinical phenotype of enthesitis related arthritis (ERA). | Gulati, R., et al. 2021. Hum Immunol. 82: 615-620. PMID: 34183176
- HLA-E-restricted HIV-1-specific CD8+ T cell responses in natural infection. | Bansal, A., et al. 2021. J Clin Invest. 131: PMID: 34228645
- HLA-E and HLA-F Are Overexpressed in Glioblastoma and HLA-E Increased After Exposure to Ionizing Radiation. | Hrbac, T., et al. 2022. Cancer Genomics Proteomics. 19: 151-162. PMID: 35181585
- Primary and secondary functions of HLA-E are determined by stability and conformation of the peptide-bound complexes. | Walters, LC., et al. 2022. Cell Rep. 39: 110959. PMID: 35705051
- HLA-E-restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD. | Vietzen, H., et al. 2023. Blood. 141: 1560-1573. PMID: 36477802
- Co-expression of HLA-E and HLA-G on genetically modified porcine endothelial cells attenuates human NK cell-mediated degranulation. | Cross-Najafi, AA., et al. 2023. Front Immunol. 14: 1217809. PMID: 37529053
- CD8+ T cell targeting of tumor antigens presented by HLA-E. | Iyer, RF., et al. 2024. Sci Adv. 10: eadm7515. PMID: 38728394
- HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer. | Ranti, D., et al. 2024. bioRxiv.. PMID: 39282294
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HLA-E Antibody (MEM-E/08) | sc-51624 | 100 µg/ml | $316.00 |